Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics

Aardema, 1998, Aneuploidy: a Report of an ECETOC Task Force, Mutat. Res., 410, 3, 10.1016/S1383-5742(97)00029-X

ABPI, 1999a. Compendium of Data Sheets, Eskazole tablets. Datapharm Publications, London, p. 1595.

ABPI, 1999b. Compendium of Data Sheets, Vermox tablets. Datapharm Publications, London, p. 671.

Amri, 1987, Sulphoxidation of Albendazole by FAD-containing and cytochrome P450-dependent mono-oxygenases from pig liver microsomes, Xenobiotica, 17, 1159, 10.3109/00498258709167408

Amri, 1988, Albendazole sulfonation by rat liver P-450c, J. Pharmacol. Exp. Ther., 246, 758

Andrews, 1983, Praziquantel, Med. Res. Rev., 3, 147, 10.1002/med.2610030204

Bekhti, 1987, Cimetidine increases serum mebendazole concentrations. Implications for treatment of hepatic hydatid cysts, Br. J. Clin. Pharmacol., 24, 390, 10.1111/j.1365-2125.1987.tb03186.x

Bittencourt, 1982, Phenytoin and carbamezepine decrease oral bioavailability of praziquantel, Neurology, 42, 493

Braithwaite, 1982, Clinical pharmacokinetics of high dose Mebendazole in patients treated for cystic hydatid disease, Eur. J. Clin. Pharmacol., 22, 161, 10.1007/BF00542462

Bühring, 1978, Metabolism of praziquantel in man, Eur. J. Drug Metab. Pharmacokinet., 3, 179, 10.1007/BF03189504

Capece, 2000, Pharmacokinetic behaviour of Albendazole sulfoxide enantiomers in male and female sheep, Vet. Res. Commun., 24, 339, 10.1023/A:1006496122684

Committee on Mutagenicity, 1996. Aneuploidy in Sections 2.17 and Section 2.18 in Annual Report, UK Department of Health, HMSO, London.

1998, 1

Dawson, 1985, The pharmacokinetics and bioavailability of a tracer dose of (3H)-mebendazole in man, Br. J. Clin. Pharmacol., 19, 79, 10.1111/j.1365-2125.1985.tb02616.x

Delatour, 1991, Comparative enantioselectivity in the sulphoxidation of albendazole in man, dogs and rats, Xenobiotica, 21, 217, 10.3109/00498259109039463

Delatour, 1984, A correlation of the toxicity of Albendazole and oxfendazole with their free metabolites and bound residues, J. Vet. Pharmacol. Ther., 7, 139, 10.1111/j.1365-2885.1984.tb00890.x

Delatour, 1991, Chiral behaviour of the metabolite Albendazole sulphoxide in sheep, goats and cattle, Res. Vet. Sci., 50, 134, 10.1016/0034-5288(91)90095-6

Dollery, 1999, Albendazole, 1, A51

Dollery, 1999, Mebendazole, 2, M12

Dollery, 1999, Praziquantel, 2, P184

2000, 1

Edwards, 1988, Clinical pharmacokinetics of anthelminthic drugs, Clin. Pharmacokinet., 15, 67, 10.2165/00003088-198815020-00001

EMEA-European Medicines Evaluation Agency, 1996. Praziquantel Summary Report by CVMP. EMEA/MRL/141/96 September 1996. EMEA, London.

EMEA-European Medicines Evaluation Agency, 1997. Albendazole Summary Report by CVMP. EMEA/MRL/247/97-Final. EMEA, London.

EMEA-European Medicines Evaluation Agency, 1999. Mebendazole Summary Report by CVMP. EMEA/MRL/625/99-Final. July 1999. EMEA, London.

EMEA-European Medicines Evaluation Agency, 2001. Mebendazole Summary Report 2 by CVMP. EMEA/MRL/781/01-Final. March 2001. EMEA, London.

Fargetton, 1986, Sulfoxidation of Albendazole by a cytochrome P-450 independent monooxygenase from rat liver microsomes, Vet. Res. Commun., 10, 314, 10.1007/BF02213995

Frohberg, 1982, Propriedades farmocinéticas, farmacologicas y toxicológicas, Salud Publica Mex., 24, 605

Frohberg, 1984, Results of toxicological studies on praziquantel, Arzneim-Forsch/Drug Res., 34, 1137

Frohberg, 1989, The toxicological profile of praziquantel in comparison to other anthelminthics drugs, Acta Leidensia, 57, 201

Frohberg, 1981, Toxicological profile of praziquantel, a new drug against cestode and schistosome infections, as compared to some other schistosomicides, Arzneim-Forsch/Drug Res., 31, 555

Gotschall, 1990, The metabolism of benzimidazole anthelminthics, Parasitol. Today, 6, 115, 10.1016/0169-4758(90)90228-V

Gray, J., 1999. Mebendazole: commentary on the mutagenic potential. Report from Covance Laboratories, Harrogate, UK, to the Janssen Research Foundation; 7th March, 1999, pp. 1–31.

Gyurik, 1981, Metabolism of albendazole in cattle, sheep, rats and mice, Drug Met. Disposit., 9, 503

Homeida, 1994, Pharmacokinetic interaction between praziquantel and Albendazole in Sudanese men, Ann. Trop. Med. Parasitol., 88, 551, 10.1080/00034983.1994.11812903

JECFA, 1989a. Albendazole: in Evaluation of Certain Veterinary Drug Residues in Food. In: Thirty-fourth Report of the Joint WHO/FAO Expert Committee on Food Additives, WHO, Geneva, pp. 14-19.

JECFA, 1989b. Albendazole. In: JECFA Food Additives Series 25. Prepared by the Thirty-fourth Meeting of the Joint WHO/FAO Expert Committee on Food Additives, WHO, Geneva, pp. 3-29.

Justel, 1994, Influence of ethanol on gastric absorption and metabolism of albendazole and Mebendazole, Drug Alcohol Depend., 36, 49, 10.1016/0376-8716(94)90009-4

Kramers, 1991, Review of the genotoxicity and carcinogenicity of antischistosomal drugs: Is there a case for a study of mutation epidemiology?, Mutat. Res., 257, 49, 10.1016/0165-1110(91)90019-R

Mandour, 1990, Pharmacokinetics of praziquantel in healthy volunteers and patients with schistosomiasis, Trans. R. Soc. Trop. Med. Hyg., 84, 389, 10.1016/0035-9203(90)90333-A

Martindale's Extra Pharmacopoeia, 1993a. In: Reynolds, J.R. (Ed.), Albendazole, 30th Edition. Pharmaceutical Press, London, p. 43.

Martindale's Extra Pharmacopoeia, 1993b. In: Reynolds, J.R. (Ed.), Mebendazole, 30th Edition. Pharmaceutical Press, London, p. 46–47.

Martindale's Extra Pharmacopoeia, 1993c. In: Reynolds, J.R. (Ed.), Praziquantel, 30th Edition. Pharmaceutical Press, London, p. 52–53.

Marques, 1999, Enantioselective kinetic disposition of albendazole sulfoxide in patients with neurocysticercosis, Chirality, 11, 218, 10.1002/(SICI)1520-636X(1999)11:3<218::AID-CHIR8>3.0.CO;2-G

Masimirembwa, 1994, Characterization of praziquantel metabolism by rat liver microsomes using cytochrome P450 inhibitors, Biochem. Pharmacol., 48, 1779, 10.1016/0006-2952(94)90464-2

Masimirembwa, 1994, The effect of chloroquine on the pharmacokinetics of praziquantel in rats and humans, Biopharm. Drug Dispos., 15, 33, 10.1002/bdd.2510150103

Moroni, 1995, Chiral sulfoxidation of Albendazole by the flavin-adenine dinucleotide-containing and cytochrome P450-dependent monooxygenases from rat liver microsomes, Drug Metab. Dispos., 23, 160

NOAH, 2001. Compendium of Data Sheets for Veterinary Products 2001-2002. NOAH, Middlesex.

Okelo, 1993, Pharmacokinetics of albendazole in children with hydatid disease, E. Afr. Med. J., 70, 643

PDR, 2001a. Albenza™, 55th ed. Medical Economics, NJ, pp. 3058–3059.

PDR, 2001b. Vermox®, 55th Edition. Medical Economics, NJ, p. 1839.

PDR, 2001c. Biltricide®, 55th Edition. Medical Economics, NJ, pp. 346–347.

Penicaut, 1983, Pharmacokinetics and urinary metabolism of albendazole in man, Bull. Soc. Pathol. Exot. Filiales., 75, 698

Pütter, 1978, Quantitative studies on the occurrence of praziquantel in milk and plasma of lactating women, Eur. J. Drug. Metabol. Pharmacokinet., 4, 193, 10.1007/BF03189426

Rawden, 2000, Relative contribution of cytochromes P450 and flavin-containing monooxygenases to the metabolism of Albendazole by human liver microsomes, Br. J. Clin. Pharmacol., 49, 313, 10.1046/j.1365-2125.2000.00170.x

Sanchez, 2000, Enhanced plasma and target tissue availabilities of albendazole and albendazole sulphoxide in fasted calves: evaluation of different fasting intervals, J. Vet. Pharmacol. Ther., 23, 193, 10.1046/j.1365-2885.2000.00265.x

Sanchez, 2000, Comparative availability of two oral dosage forms of albendazole in the dog, Vet. J., 160, 153, 10.1053/tvjl.2000.0484

Souhaili-El Amri, 1988, Inducing effect of albendazole on rat liver drug-metabolizing enzymes and metabolite pharmacokinetics, Toxicol. Appl. Pharmacol, 92, 141, 10.1016/0041-008X(88)90236-0

Souhaili-El Amri, 1988, Albendazole sulfonation by rat liver cytochrome P-450c, J Pharmacol. Exp. Ther., 246, 758

Thamavit, 1992, Repeated exposure to Opisthorchis viverrini and treatment with the antihelminthic praziquantel lacks carcinogenic potential, Carcinogenesis, 13, 309, 10.1093/carcin/13.2.309

Witassek, 1981, Chemotherapy of alveolar echinococcosis; comparison of plasma Mebendazole concentrations in animals and man, Eur. J. Clin. Pharmacol., 20, 427, 10.1007/BF00542095

Zeugin, 1990, Therapeutic monitoring of albendazole: a high-performance liquid chromatography method for determination of its active metabolite albendazole sulfoxide, Ther. Drug Monit., 12, 187, 10.1097/00007691-199003000-00013